Latest News and Press Releases

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in...

Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers New data...

Wildermuth Fund investors that lost money are notified to contact BFA before the December 29, 2025 securities fraud class action deadline.

Scripps reports Q3 2025 financial results

Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan,...

Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a...

– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – ...

Pharming Group reports Q3 2025 results with significant growth in revenue, profit, and cash flow driven by rare disease portfolio performance.

Third Quarter 2025 Revenue Totaled $12.6 Million, an Increase of 0.3% Year-Over-Year Third Quarter 2025 Net Income Attributable to Common Stockholders Totaled $6.7 Million, Funds from Operations...

LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Elev8 New Media (“Elev8”), an award-winning boutique public relations agency that specializes in results-driven media relations and social media...